USPTO Art Unit 1647 Prosecution Statistics

Art Unit Information

Art Unit: 1647
Group: 1640
Tech Center: 1600
Total Cases: 14,323
Last Active: July 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
192752035T4 BINDING POLYPEPTIDES AND USES THEREOFJuly 2025February 2026Allow710NoNo
19231212MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO TREAT DUCHENNE MUSCULAR DYSTROPHYJune 2025September 2025Allow410NoNo
19228960TREATMENT METHODJune 2025January 2026Abandon800NoNo
19229468ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOFJune 2025November 2025Allow610NoNo
19211660COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECTMay 2025August 2025Allow301YesNo
19189163COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING AN OLIGONUCLEOTIDE TO A SUBJECTApril 2025September 2025Allow510NoNo
19180751Methods and compositions for improving the immune response against viral pathogensApril 2025December 2025Abandon810NoNo
19094954RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of UseMarch 2025October 2025Allow611YesNo
19085020TSLP-Binding Molecules, IL-33-Binding Molecules, and Bispecific Antigen-Binding Molecules, and Uses ThereofMarch 2025October 2025Allow710NoNo
19085184ANTI-HUMAN INTERLEUKIN 36 RECEPTOR MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF TO TREAT DISEASEMarch 2025October 2025Allow711YesNo
19066279EXOSOME SYSTEMS, PRODUCTS AND METHODSFebruary 2025April 2025Allow100NoNo
19067809Nectin-4 binding miniproteins, conjugates and methods of use thereofFebruary 2025July 2025Allow410NoNo
19065946MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING OF EXON 44 OF DYSTROPHIN IN A SUBJECTFebruary 2025May 2025Allow201YesNo
19066035Complexes Comprising An Anti-transferrin Receptor Antibody Linked to An Oligonucleotide And Method Of Delivering Oligonucleotide To A SubjectFebruary 2025June 2025Allow400YesNo
19058780ANTIBODIES THAT BIND THE SPIKE PROTEIN OF SARS-COV-2February 2025September 2025Allow601YesNo
19046824MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPINGFebruary 2025May 2025Allow411YesNo
19033679ANTIBODIES TARGETING IL3January 2025May 2025Allow411NoNo
19019930GAMMA DELTA T CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS, AND PRODUCTION METHOD THEREFORJanuary 2025August 2025Allow710YesNo
19006997CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USEDecember 2024July 2025Allow610NoNo
19005529TL1A BINDING PROTEINS AND METHODS OF USEDecember 2024September 2025Allow821YesNo
19005160BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMADecember 2024September 2025Allow910NoNo
18988612SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATIONDecember 2024April 2025Allow410NoNo
18979795ANTIBODIES THAT BIND INTERLEUKIN 13 AND METHODS OF USEDecember 2024May 2025Allow511YesNo
18964217ANTI-FGF23 ANTIBODY OR ANTIBODY FRAGMENT THEREOFNovember 2024December 2025Allow1321NoNo
18956856TREATMENT METHODNovember 2024June 2025Abandon700NoNo
18942121TNF-ALPHA VARIANT FUSION MOLECULESNovember 2024July 2025Allow811NoNo
18940209METHOD OF USING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYNovember 2024March 2025Allow511YesNo
18939894COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECTNovember 2024April 2025Allow511YesNo
18927497POLYPEPTIDE COMPRISING A SINGLE-DOMAIN ANTIBODY VARIABLE REGION THAT BINDS DELTA-LIKE LIGAND 3 (DLL3) AND METHOD OF USE THEREOF TO MAKE A RADIONUCLIDE COMPLEXOctober 2024April 2025Allow511YesNo
18924707VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATIONOctober 2024February 2025Allow410NoNo
18920375ANTI-CD19 ANTIBODY DRUG CONJUGATESOctober 2024July 2025Allow911YesNo
18901784DENDRITIC CELL PREPARATION AND PREPARATION METHOD THEREOFSeptember 2024July 2025Allow920NoNo
18896799METHOD OF TREATING AN INTERLEUKIN-11-ASSOCIATED OR -MEDIATED FIBROTIC DISEASE OR CONDITION BY ADMINISTERING AN ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODYSeptember 2024March 2025Allow611NoNo
18887997EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAMESeptember 2024October 2025Allow1320YesNo
18844737ANTIBODIES THAT INHIBIT ERYTHROPOIETIN RECEPTOR ACTIVATION AND METHODS OF USE THEREOF TO TREAT CANCERSeptember 2024January 2026Allow1621YesNo
18844732METHOD OF TREATING CANCER BY ADMINISTERING AN INHIBITOR OF ERYTHROPOIETIN RECEPTOR ACTIVITY COMPRISING EITHER ERYTHROPOIETIN RECEPTOR OR ERYTHROPOIETIN PROTEINSeptember 2024August 2025Allow1111YesNo
18806325BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND ENCODING POLYNUCLEOTIDES, VECTORS AND CELLS THEREOFAugust 2024July 2025Allow1111YesNo
18772062TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOFJuly 2024October 2024Allow310NoNo
18759724COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHYJune 2024June 2025Allow1211YesNo
18753823Albumin Bound Macromolecule Tri-Agonist Activating GLP-1/GIP/Glucagon ReceptorsJune 2024December 2025Allow1831NoNo
18753994METHOD OF MONITORING ANTI-TNF THERAPY IN A SUBJECT SUFFERING FROM RHEUMATOID ARTHRITIS BASED IN PART ON A TRAINED MACHINE LEARNING CLASSIFIERJune 2024September 2025Allow1511YesNo
18666190ANTI-CXCR2 ANTIBODIES AND USES THEREOFMay 2024September 2025Abandon1601NoNo
18656654COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDEMay 2024August 2024Allow411NoNo
18656672MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDEMay 2024August 2024Allow411YesNo
18651734MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHODS OF USE THEREOF TO TARGET DYSTROPHIN AND TO TREAT DUCHENNE MUSCULAR DYSTROPHYMay 2024January 2025Allow911YesNo
18651002NOTCH4 ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATING AIRWAY INFLAMMATIONApril 2024December 2024Allow810NoNo
18650019PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASEApril 2024October 2025Allow1711NoNo
18642478APPLICATION OF A NANOBODY TARGETING ON IL-6RAApril 2024January 2025Allow920NoNo
18629444ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE WHICH BINDS CLAUDIN-6 and CLAUDIN-9April 2024September 2024Allow611NoNo
18624726DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATIONApril 2024July 2025Abandon1510NoNo
18619759TNFR2 Agonists with Improved StabilityMarch 2024September 2024Allow610YesNo
18618991FORMULA OF NEUREGULIN PREPARATIONMarch 2024March 2026Abandon2410NoNo
18695013COLLAGEN HYDROLYSATE FOR USE IN PREVENTION AND/OR TREATMENT OF POST INTENSIVE CARE SYNDROME (PICS)March 2024December 2024Allow901YesNo
18606662PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024December 2025Allow2200NoNo
18606648PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024February 2025Allow1100NoNo
18599849PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024December 2024Allow900NoNo
18599838PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024November 2024Allow800YesNo
18599924PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024January 2025Allow1100NoNo
18599860PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024January 2025Allow1000NoNo
18599888PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024January 2025Allow1000NoNo
18594400TIGIT- AND LIGHT-BASED CHIMERIC PROTEINSMarch 2024October 2025Abandon2001NoNo
18593108ANTI-HUMAN INTERLEUKIN-33 MONOCLONAL ANTIBODY AND USE THEREOFMarch 2024March 2025Allow1220NoNo
18593157ANTI-HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP) MONOCLONAL ANTIBODY AND USE THEREOF TO TREAT DISEASEMarch 2024June 2025Allow1511YesNo
18590853ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODIESFebruary 2024September 2024Allow611YesNo
18587502BISPECIFIC ANTIBODY THAT BINDS TO CD116 AND CD131February 2024August 2024Allow610YesNo
18585158PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSFebruary 2024October 2024Allow800YesNo
18444110ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATIONFebruary 2024September 2025Abandon1911NoNo
18443970MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THIOREDOXIN 1 AND METHODS OF USE THEREOF FOR BREAST CANCER DIAGNOSISFebruary 2024October 2025Allow2011YesNo
18443945MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THIOREDOXIN 1 AND METHODS OF USE THEREOF FOR BREAST CANCER DIAGNOSISFebruary 2024October 2025Allow2011YesNo
18444102METHODS FOR INHIBITING DIAZEPAM BINDING PROTEINFebruary 2024February 2025Allow1220NoNo
18442906ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1February 2024March 2026Abandon2511NoNo
18437617CONNEXIN 43 (Cx43) HEMICHANNEL-BINDING ANTIBODIESFebruary 2024August 2025Allow1811NoNo
18436546METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONSFebruary 2024October 2025Abandon2001NoNo
18436802IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory DiseasesFebruary 2024March 2026Allow2510NoNo
18431764NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTIBODIES AND OTHER PROTEINS THAT BIND FOLATE RECEPTOR ALPHAFebruary 2024January 2025Allow1211NoNo
18429738Method for Producing an Active Hepatocyte Growth Factor (HGF)February 2024May 2025Allow1610NoNo
18425844ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATESJanuary 2024June 2025Allow1620NoNo
18420510ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USEJanuary 2024November 2025Abandon2111NoNo
18417063COMPOSITIONS AND METHODS FOR CANCER THERAPYJanuary 2024December 2024Abandon1110NoNo
18412403EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAMEJanuary 2024August 2024Allow710YesNo
18412412HEMATOPOIETIC STEM CELLS IN COMBINATORIAL THERAPY WITH IMMUNE CHECKPOINT INHIBITORS AGAINST CANCERJanuary 2024December 2025Allow2310NoNo
18410568DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINESJanuary 2024July 2025Abandon1801NoNo
18403553COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSEJanuary 2024October 2025Allow2110NoNo
18401874Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 AntibodyJanuary 2024July 2025Abandon1801NoNo
18400943METHODS FOR MAKING RADIOLABELED ANTI-MET BINDING PROTEINSDecember 2023December 2025Allow2421YesNo
18396187ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOFDecember 2023August 2025Allow2010NoNo
18396206FLT3L-BASED CHIMERIC PROTEINSDecember 2023December 2025Abandon2401NoNo
18391233COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASEDecember 2023July 2025Allow1910YesNo
18542929POLYNUCLEOTIDES ENCODING ANTI-GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP1R) ANTAGONIST ANTIBODIESDecember 2023June 2025Allow1711NoNo
18542451METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDSDecember 2023August 2025Abandon2001YesNo
18538465ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOFDecember 2023May 2025Abandon1710NoNo
18538748COMPOSITION COMPRISING ANTI-GLIADIN ANTIBODIES AND METHOD OF USE THEREOF TO DETECT GLIADIN IN A SAMPLEDecember 2023August 2025Allow2111YesNo
18534366USE OF THE EXTRACELLULAR DOMAIN OF TRANSFERRIN RECEPTOR 2 FOR THE DIAGNOSIS OF DISEASEDecember 2023February 2026Abandon2621NoNo
18529915BISPECIFIC CHIMERIC ANTIGEN RECEPTOR THAT BINDS CD19 AND CD20, ENCODING NUCLEIC ACID MOLECULES THEREOF AND METHODS OF USE THEREOF TO TREAT CANCERDecember 2023November 2025Allow2311NoNo
18528957METHOD OF TREATING AN OCULAR CONDITION BY ADMINISTERING MULTISPECIFIC ANTIBODIES THAT ACTIVATES TIE2 AND BINDS A RECEPTOR TYROSINE KINASE AGONISTDecember 2023April 2025Allow1701NoNo
18523048METHOD OF REDUCING SERUM AMYLOID A (SAA) PROTEIN LEVELS IN A PATIENT BY ADMINISTERING AN INTERLEUKIN-33 (IL-33) ANTIBODYNovember 2023December 2025Allow2511YesNo
18509252BISPECIFIC ANTI-CCL2 ANTIBODIESNovember 2023April 2024Allow511YesNo
18504723METHODS OF TREATING AN EYE DISORDERNovember 2023September 2024Allow1010NoNo
18497432FOOD-ALLERGEN SPECIFIC ANTIBODY COMPOSITIONSOctober 2023August 2024Allow1011NoNo
18496397Serum Albumin-Binding Fibronectin Type III DomainsOctober 2023January 2026Allow2710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1647.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
105
Examiner Affirmed
85
(81.0%)
Examiner Reversed
20
(19.0%)
Reversal Percentile
3.5%
Lower than average

What This Means

With a 19.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1285
Allowed After Appeal Filing
228
(17.7%)
Not Allowed After Appeal Filing
1057
(82.3%)
Filing Benefit Percentile
3.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1647 - Prosecution Statistics Summary

Executive Summary

Art Unit 1647 is part of Group 1640 in Technology Center 1600. This art unit has examined 14,323 patent applications in our dataset, with an overall allowance rate of 55.2%. Applications typically reach final disposition in approximately 31 months.

Comparative Analysis

Art Unit 1647's allowance rate of 55.2% places it in the 11% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1647 receive an average of 1.71 office actions before reaching final disposition (in the 35% percentile). The median prosecution time is 31 months (in the 46% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.